Riyazuddin Mohammad Shaik

InstitutionHamad Medical Corporation
AddressDoha
Qatar
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 11 Covid-19 publications, with a maximum of 3 publications in May 2021
    All Publications
    Bar chart showing 11 publications over 2 distinct years, with a maximum of 10 publications in 2021
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Abu-Raddad LJ, Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, Tang P, Malek JA, Coyle P, Ayoub HH, Al Kanaani Z, Al Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul Rahim HF, Nasrallah GK, Al Kuwari MG, Al Romaihi HE, Al-Thani MH, Al Khal A, Butt AA, Bertollini R. Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses. J Travel Med. 2021 10 11; 28(7). PMID: 34050372.
      Citations: 6     Fields:    Translation:Humans
    2. Abu-Raddad LJ, Chemaitelly H, Malek JA, Ahmed AA, Mohamoud YA, Younuskunju S, Ayoub HH, Al Kanaani Z, Al Khal A, Al Kuwari E, Butt AA, Coyle P, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul Rahim HF, Yassine HM, Al Kuwari MG, Al Romaihi HE, Al-Thani MH, Bertollini R. Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting. Clin Infect Dis. 2021 10 05; 73(7):e1830-e1840. PMID: 33315061.
      Citations: 57     Fields:    Translation:HumansPHPublic Health
    3. Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, Tang P, Hasan MR, Malek JA, Coyle P, Ayoub HH, Al Kanaani Z, Al Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul Rahim HF, Nasrallah GK, Al Kuwari MG, Al Romaihi HE, Al-Thani MH, Al Khal A, Butt AA, Bertollini R, Abu-Raddad LJ. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med. 2021 09; 27(9):1614-1621. PMID: 34244681.
      Citations: 34     Fields:    Translation:Humans
    4. Nasrallah GK, Dargham SR, Shurrab F, Al-Sadeq DW, Al-Jighefee H, Chemaitelly H, Al Kanaani Z, Al Khal A, Al Kuwari E, Coyle P, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Rahim HFA, Yassine HM, Al Kuwari MG, Qotba H, Al Romaihi HE, Tang P, Bertollini R, Al-Thani MH, Althani AA, Abu-Raddad LJ. Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population. Sci Rep. 2021 06 04; 11(1):11837. PMID: 34088944.
      Citations: 4     Fields:    Translation:Humans
    5. Coyle PV, Chemaitelly H, Ben Hadj Kacem MA, Abdulla Al Molawi NH, El Kahlout RA, Gilliani I, Younes N, Al Anssari GAAA, Al Kanaani Z, Al Khal A, Al Kuwari E, Butt AA, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul Rahim HF, Nasrallah GK, Yassine HM, Al Kuwari MG, Al Romaihi HE, Al-Thani MH, Bertollini R, Abu-Raddad LJ. SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals. iScience. 2021 Jun 25; 24(6):102646. PMID: 34056566.
      Citations: 10     
    6. Citations: 5     
    7. Jeremijenko A, Chemaitelly H, Ayoub HH, Alishaq M, Abou-Samra AB, Al Ajmi JAAA, Al Ansari NAA, Al Kanaani Z, Al Khal A, Al Kuwari E, Al-Mohammed A, Al Molawi NHA, Al Naomi HM, Butt AA, Coyle P, El Kahlout RA, Gillani I, Kaleeckal AH, Masoodi NA, Thomas AG, Nafady-Hego H, Latif AN, Shaik RM, Younes NBM, Rahim HFA, Yassine HM, Al Kuwari MG, Al Romaihi HE, Al-Thani MH, Bertollini R, Abu-Raddad LJ. Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar. Emerg Infect Dis. 2021 05; 27(5):1343-1352. PMID: 33900174.
      Citations: 8     Fields:    Translation:Humans
    8. Abu-Raddad LJ, Chemaitelly H, Coyle P, Malek JA, Ahmed AA, Mohamoud YA, Younuskunju S, Ayoub HH, Al Kanaani Z, Al Kuwari E, Butt AA, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul Rahim HF, Nasrallah GK, Yassine HM, Al Kuwari MG, Al Romaihi HE, Al-Thani MH, Al Khal A, Bertollini R. SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. EClinicalMedicine. 2021 May; 35:100861. PMID: 33937733.
      Citations: 22     
    9. Ayoub HH, Chemaitelly H, Makhoul M, Al Kanaani Z, Al Kuwari E, Butt AA, Coyle P, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul Rahim HF, Nasrallah GK, Yassine HM, Al Kuwari MG, Al Romaihi HE, Al-Thani MH, Bertollini R, Al Khal A, Abu-Raddad LJ. Epidemiological impact of prioritising SARS-CoV-2 vaccination by antibody status: mathematical modelling analyses. BMJ Innov. 2021 Apr; 7(2):327-336. PMID: 34192020.
      Citations: 6     
    10. Ayoub HH, Chemaitelly H, Seedat S, Makhoul M, Al Kanaani Z, Al Khal A, Al Kuwari E, Butt AA, Coyle P, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Rahim HA, Yassine HM, Al Kuwari MG, Al Romaihi HE, Al-Thani MH, Bertollini R, Abu Raddad LJ. Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19. J Glob Health. 2021 Jan 16; 11:05005. PMID: 33643638.
      Citations: 16     Fields:    Translation:HumansPHPublic Health
    11. Abu-Raddad LJ, Chemaitelly H, Malek JA, Ahmed AA, Mohamoud YA, Younuskunju S, Al Kanaani Z, Al Khal A, Al Kuwari E, Butt AA, Coyle P, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul Rahim HF, Yassine HM, Al Kuwari MG, Al Romaihi HE, Al-Thani MH, Bertollini R. Two prolonged viremic SARS-CoV-2 infections with conserved viral genome for two months. Infect Genet Evol. 2021 03; 88:104684. PMID: 33352320.
      Citations: 3     Fields:    Translation:Humans
    Shaik's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (31)
    Explore
    _
    Co-Authors (83)
    Explore
    _
    Similar People (60)
    Explore
    _